Susceptibility to Antibiotics: A Comprehensive Review of the Data Obtained and in Animal Models
Overview
Infectious Diseases
Microbiology
Authors
Affiliations
The antibiotic classes that are recommended for tularaemia treatment are the aminoglycosides, the fluoroquinolones and the tetracyclines. However, cure rates vary between 60 and 100% depending on the antibiotic used, the time to appropriate antibiotic therapy setup and its duration, and the presence of complications, such as lymph node suppuration. Thus, antibiotic susceptibility testing (AST) of strains remains of primary importance for detection of the emergence of antibiotic resistances to first-line drugs, and to test new therapeutic alternatives. However, the AST methods reported in the literature were poorly standardized between studies and AST data have not been previously evaluated in a comprehensive and comparative way. The aim of the present review was to summarize experimental data on antibiotic susceptibilities of obtained in acellular media, cell models and animal models since the introduction of fluoroquinolones in the treatment of tularaemia in 1989. We compiled MIC data of 33 antibiotics (including aminoglycosides, fluoroquinolones, tetracyclines, macrolides, β-lactams, chloramphenicol, rifampicin, and linezolid) against 900 strains (504 human strains), including 107 subsp. (type A), 789 subsp. (type B) and four subsp. strains, using various AST methods. Specific culture media were identified or confirmed as unsuitable for AST of . Overall, MICs were the lowest for ciprofloxacin (≤ 0.002-0.125 mg/L) and levofloxacin, and ranged from ≤ 0.016 to 2 mg/L for gentamicin, and 0.064 to 4 mg/L for doxycycline. No resistant strain to any of these antibiotics was reported. Fluoroquinolones also exhibited a bactericidal activity against intracellular and lower relapse rates in animal models when compared with the bacteriostatic compound doxycycline. As expected, lower MIC values were found for macrolides against type A and biovar I type B strains, compared to biovar II type B strains. The macrolides were more effective against grown in phagocytic cells than in acellular media.
Non-vaccinal prophylaxis of tularemia.
Maurin M, Hennebique A, Brunet C, Ponderand L, Pelloux I, Boisset S Front Microbiol. 2024; 15:1507469.
PMID: 39669787 PMC: 11635305. DOI: 10.3389/fmicb.2024.1507469.
infection in a patient with pulmonary infection and pancreatitis in Italy.
Rigamonti S, Olivieri E, Vicari N, Scaltriti E, Bazzucchi M, Lodola C IDCases. 2024; 37:e02038.
PMID: 39184331 PMC: 11342269. DOI: 10.1016/j.idcr.2024.e02038.
Development, Strategies, and Challenges for Tularemia Vaccine.
Moradkasani S, Maurin M, Salek Farrokhi A, Esmaeili S Curr Microbiol. 2024; 81(5):126.
PMID: 38564047 DOI: 10.1007/s00284-024-03658-0.
Marmosets as models of infectious diseases.
Herron I, Laws T, Nelson M Front Cell Infect Microbiol. 2024; 14:1340017.
PMID: 38465237 PMC: 10921895. DOI: 10.3389/fcimb.2024.1340017.
Thoracic manifestations of tularaemia: a case series.
Vacca M, Wilhelms B, Zange S, Avsar K, Gesierich W, Heiss-Neumann M Infection. 2024; 52(4):1607-1614.
PMID: 38457094 DOI: 10.1007/s15010-024-02204-1.